Abstract
On 11 February 2016, the Medicines and Healthcare Products Regulatory Agency announced that nivolumab, a new medicine for advanced renal cell carcinoma, will be available via the Early Access to Medicines Scheme. Kim Edmonds discusses the impact of this for patients with kidney cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.